Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1248144 | 1.00 | CYP1A2 (0.32) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL1248148 | 1.00 | CYP1A2 (0.32) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL1250512 | 0.87 | CYP2D6 (0.40) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL1250510 | 0.87 | CYP2D6 (0.40) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL1250507 | 0.87 | CYP2D6 (0.40) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL994687 | 0.78 | TSHR (0.43) | ALDH1A1GAA | |
| SCHEMBL994688 | 0.78 | TSHR (0.43) | ALDH1A1GAA | |
| SCHEMBL994689 | 0.78 | TSHR (0.43) | ALDH1A1GAA | |
| SCHEMBL25166710 | 0.78 | ARG1 (0.33) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 | |
| SCHEMBL28441328 | 0.78 | ARG1 (0.33) | CYP1A2CYP2D6ALOX15CYP2C19SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279737-B1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2279737-A1 | Heterocyclic compounds that are active as beta lactamase inhibitors | NOVEXEL (FR) | 2011-02-02 | — | — | EP | disclosed |
| EP-1480644-B1 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | NOVEXEL (FR) | 2010-10-13 | — | — | EP | disclosed |
| EP-1480644-A2 | NOVEL HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA+LACTAMASES | Aventis Pharma S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| EP-1307457-B1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2004-04-07 | — | — | EP | disclosed |
| WO-2003063864-A2 | HETEROCYCLIC COMPOUNDS WHICH ARE ACTIVE AS INHIBITORS OF BETA LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2003-08-07 | — | — | WO | disclosed |
| EP-1307457-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010172-A1 | AZABICYCLIC COMPOUNDS, PREPARATION THEREOF AND USE AS MEDICINES, IN PARTICULAR AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA SA (FR) | 2002-02-07 | — | — | WO | disclosed |